# Using ctDNA to Guide Treatment Decisions for Stage III Gastric Cancer

> **NCT06939439** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 416 (estimated)

## Conditions studied

- Gastric Cancer Stage III

## Interventions

- **DRUG:** Tislelizumab + SOX Chemotherapy
- **DRUG:** SOX Chemotherapy

## Key facts

- **NCT ID:** NCT06939439
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-12-01
- **Primary completion:** 2026-12-31
- **Final completion:** 2029-12-31
- **Target enrollment:** 416 (ESTIMATED)
- **Last updated:** 2025-07-01

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06939439

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06939439, "Using ctDNA to Guide Treatment Decisions for Stage III Gastric Cancer". Retrieved via AI Analytics 2026-09-28 from https://api.ai-analytics.org/clinical/NCT06939439. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*